Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
Our mission is to educate and provide an affordable early detection system for the...
Our mission is to educate and provide an afford...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to ...
Dermira is a biopharmaceutical company dedicate...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Join the National Investor Network and get the latest information with your interests in mind.